We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





LumiraDx Highlights Next-Generation Point of Care Solutions at MEDLAB Middle East Virtual Event

By LabMedica International staff writers
Posted on 21 Jun 2021
LumiraDx (London, UK) attended the virtual event of this year’s Medlab Middle East, the leading medical laboratory exhibition in the region for over 20 years. More...
The event brought together over 23,000 medical laboratory, healthcare and trade professionals from more than 140 countries.

In 2021 Medlab Middle East was run as a hybrid event and once again co-locating with Arab Health, bringing together the healthcare and laboratory communities. This year’s online event allowed delegates to network with industry peers, meet virtually, explore the latest products and attend educational sessions. LumiraDx exhibited online for the first time at Medlab Middle East and introduced its transformational point of care solution, the innovative LumiraDx Platform which is designed to perform a broad menu of tests, including infectious disease, cardiovascular disease, diabetes, and coagulation disorders and deliver lab-comparable performance with results in less than 12 minutes. The next generation point of care diagnostic system combines a small, portable instrument; microfluidic test strip; simple, standardized workflow; and seamless, secure digital connectivity to the Cloud and hospital IT systems. It is designed to be affordable and accessible for healthcare providers globally, and to strengthen community-based healthcare.

LumiraDx also highlighted its COVID-19 testing solutions at MEDLAB Middle East 2021, including its recently launched SARS-CoV-2 Antigen Test for use on the LumiraDx Platform which delivers results in 12 minutes with 97.6% PPA to an EUA approved RT-PCR method within the first 12 days of symptom onset. The use of a LumiraDx SARS-CoV-2 Ag Test on the LumiraDx Instrument enables the physician to verify infection quickly, begin proper treatment and to initiate isolation precautions helping prevent further spread of infection. Also on display was the LumiraDx SARS-CoV-2 Ag Pool Test, a rapid microfluidic immunofluorescence assay for the qualitative detection of the nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens pooled from up to five individuals suspected of COVID-19 or up to five asymptomatic individuals. Used with the LumiraDx Platform, the test offers a rapid, scalable and cost-effective screening solution for infectious individuals. The company also showcased the LumiraDx SARS-CoV-2 Ab Test, a microfluidic immunofluorescence assay for the qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (capillary fingerstick or venous), plasma or serum for indication of recent or prior infection. Used with the LumiraDx Platform, the test delivers rapid results at the point of care.

Related Links:
LumiraDx


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Blood Glucose Test Strip
AutoSense Test
New
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.